{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:03:07Z","timestamp":1793314987628,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CNPq - National Council for Scientific and Technological Development, Brazil","award":["140400\/2019-2"],"award-info":[{"award-number":["140400\/2019-2"]}]},{"name":"CNPq - National Council for Scientific and Technological Development, Brazil","award":["307280\/ 2022-5"],"award-info":[{"award-number":["307280\/ 2022-5"]}]},{"name":"CNPq - National Council for Scientific and Technological Development, Brazil","award":["307.703\/2022-3"],"award-info":[{"award-number":["307.703\/2022-3"]}]},{"name":"FAPESP - Research Support Foundation of the State of S\u00e3o Paulo, Brazil","award":["2021\/10923-5"],"award-info":[{"award-number":["2021\/10923-5"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sodium-glucose cotransporter (SGLT)2 inhibitors have displayed beneficial effects on the cardiovascular system in diabetes mellitus (DM) patients. As most clinical trials were performed in Type 2 DM, their effects in Type 1 DM have not been established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the influence of long-term treatment with SGLT2 inhibitor dapagliflozin on cardiac remodeling, myocardial function, energy metabolism, and metabolomics in rats with Type 1 DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Male Wistar rats were divided into groups: Control (C, n\u2009=\u200915); DM (n\u2009=\u200915); and DM treated with dapagliflozin (DM\u2009+\u2009DAPA, n\u2009=\u200915) for 30 weeks. DM was induced by streptozotocin. Dapagliflozin 5\u00a0mg\/kg\/day was added to chow. Statistical analysis: ANOVA and Tukey or Kruskal-Wallis and Dunn.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>DM\u2009+\u2009DAPA presented lower glycemia and higher body weight than DM. Echocardiogram showed DM with left atrium dilation and left ventricular (LV) hypertrophy, dilation, and systolic and diastolic dysfunction. In LV isolated papillary muscles, DM had reduced developed tension, +dT\/dt and -dT\/dt in basal condition and after inotropic stimulation. All functional changes were attenuated by dapagliflozin. Hexokinase (HK), phosphofructokinase (PFK) and pyruvate kinase (PK) activity was lower in DM than C, and PFK and PK activity higher in DM\u2009+\u2009DAPA than DM. Metabolomics revealed 21 and 5 metabolites positively regulated in DM vs. C and DM\u2009+\u2009DAPA vs. DM, respectively; 6 and 3 metabolites were negatively regulated in DM vs. C and DM\u2009+\u2009DAPA vs. DM, respectively. Five metabolites that participate in cell membrane ultrastructure were higher in DM than C. Metabolites levels of N-oleoyl glutamic acid, chlorocresol and N-oleoyl-L-serine were lower and phosphatidylethanolamine and ceramide higher in DM\u2009+\u2009DAPA than DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Long-term treatment with dapagliflozin attenuates cardiac remodeling, myocardial dysfunction, and contractile reserve impairment in Type 1 diabetic rats. The functional improvement is combined with restored pyruvate kinase and phosphofructokinase activity and attenuated metabolomics changes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13098-023-01196-6","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T08:02:33Z","timestamp":1698739353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats"],"prefix":"10.1186","volume":"15","author":[{"given":"Eder Anderson","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Moreno","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijon Henrique Salome","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Cesar","family":"Damatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilson Masahiro","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiane Moreira","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana Urbano","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Yumi","family":"Brosler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebreia Oliveira Almeida","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Machado","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Machado","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana Erico","family":"Tanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katashi","family":"Okoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Politi","family":"Okoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"issue":"8","key":"1196_CR1","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke statistics\u20142023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93\u2013e621.","journal-title":"Circulation"},{"issue":"3","key":"1196_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/cvr\/cvac049","volume":"119","author":"RJ Phang","year":"2023","unstructured":"Phang RJ, Ritchie RH, Hausenloy DJ, Lees JG, Lim SY. Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy. Cardiovasc Res. 2023;119(3):668\u201390.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"1196_CR3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1161\/CIRCRESAHA.118.314665","volume":"124","author":"WH Dillmann","year":"2019","unstructured":"Dillmann WH. Diabetic cardiomyopathy: what is it and can it be fixed? Circ Res. 2019;124(8):1160\u20132.","journal-title":"Circ Res"},{"issue":"3","key":"1196_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10741-021-10200-y","volume":"28","author":"FR Prandi","year":"2022","unstructured":"Prandi FR, Evangelista I, Sergi D, Palazzuoli A, Romeo F. Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants. Heart Fail Rev. 2022;28(3):597\u2013606.","journal-title":"Heart Fail Rev"},{"key":"1196_CR5","doi-asserted-by":"publisher","first-page":"175720","DOI":"10.1016\/j.ejphar.2023.175720","volume":"949","author":"D Dasari","year":"2023","unstructured":"Dasari D, Goyal SG, Penmetsa A, Sriram D, Dhar A. Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function. Eur J Pharmacol. 2023;949:175720.","journal-title":"Eur J Pharmacol"},{"key":"1196_CR6","doi-asserted-by":"publisher","first-page":"154910","DOI":"10.1016\/j.metabol.2021.154910","volume":"125","author":"SS Jankauskas","year":"2021","unstructured":"Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, Gambardella J, et al. Heart Failure in Diabetes. Metabolism. 2021;125:154910.","journal-title":"Metabolism"},{"issue":"11","key":"1196_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","volume":"43","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. SGLT2 inhibitors: the statins of the 21st century. Eur Heart J. 2022;43(11):1029\u201330.","journal-title":"Eur Heart J"},{"issue":"21","key":"1196_CR8","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","volume":"386","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. Gliflozins in the management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024\u201334.","journal-title":"N Engl J Med"},{"issue":"16","key":"1196_CR9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart Failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"1196_CR10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, De Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"4","key":"1196_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"1196_CR12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"12","key":"1196_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372.","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"1196_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of Diabetes Mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"10","key":"1196_CR15","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/biomedicines9101356","volume":"9","author":"T Salvatore","year":"2021","unstructured":"Salvatore T, Caturano A, Galiero R, Di Martino A, Albanese G, Vetrano E, et al. Cardiovascular benefits from gliflozins: effects on endothelial function. Biomedicines. 2021;9(10):1356.","journal-title":"Biomedicines"},{"issue":"1","key":"1196_CR16","doi-asserted-by":"publisher","first-page":"13009","DOI":"10.1038\/s41598-019-49525-y","volume":"9","author":"JH Bae","year":"2019","unstructured":"Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 Diabetes: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):13009.","journal-title":"Sci Rep"},{"issue":"6","key":"1196_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11906-023-01240-w","volume":"25","author":"RL Sanz","year":"2023","unstructured":"Sanz RL, Inserra F, Garc\u00eda Men\u00e9ndez S, Mazzei L, Ferder L, Manucha W. Metabolic syndrome and cardiac remodeling due to mitochondrial oxidative stress involving gliflozins and sirtuins. Curr Hypertens Rep. 2023;25(6):91\u2013106.","journal-title":"Curr Hypertens Rep"},{"issue":"4","key":"1196_CR18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1210\/clinem\/dgac618","volume":"108","author":"K Edwards","year":"2023","unstructured":"Edwards K, Li X, Lingvay I. Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 Diabetes: a real-world study. J Clin Endocrinol Metab. 2023;108(4):920\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1196_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11892-022-01471-2","volume":"22","author":"H Liu","year":"2022","unstructured":"Liu H, Sridhar VS, Perkins BA, Rosenstock J, Cherney DZI. SGLT2 inhibition in type 1 Diabetes with diabetic Kidney Disease: potential cardiorenal benefits can outweigh preventable risk of diabetic ketoacidosis. Curr Diab Rep. 2022;22(7):317\u201332.","journal-title":"Curr Diab Rep"},{"issue":"1","key":"1196_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/dom.14556","volume":"24","author":"MS Hughes","year":"2022","unstructured":"Hughes MS, Bailey R, Calhoun P, Shah VN, Lyons SK, DeSalvo DJ. Off-label use of sodium glucose co\u2010transporter inhibitors among adults in type 1 Diabetes exchange registry. Diabetes Obes Metab. 2022;24(1):171\u20133.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1196_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00592-021-01686-x","volume":"58","author":"L Rao","year":"2021","unstructured":"Rao L, Ren C, Luo S, Huang C, Li X. Sodium\u2013glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 Diabetes Mellitus: meta-analysis of randomized controlled trials. Acta Diabetol. 2021;58(7):869\u201380.","journal-title":"Acta Diabetol"},{"issue":"5","key":"1196_CR22","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3390\/antiox11050982","volume":"11","author":"CM Rosa","year":"2022","unstructured":"Rosa CM, Campos DHS, Reyes DRA, Damatto FC, Kurosaki LY, Pagan LU, et al. Effects of the SGLT2 inhibition on cardiac remodeling in streptozotocin-induced diabetic rats, a model of type 1 Diabetes Mellitus. Antioxidants. 2022;11(5):982.","journal-title":"Antioxidants"},{"issue":"5","key":"1196_CR23","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s12265-022-10220-5","volume":"15","author":"HM Salah","year":"2022","unstructured":"Salah HM, Verma S, Santos-Gallego CG, Bhatt AS, Vaduganathan M, Khan MS, et al. Sodium-glucose cotransporter 2 inhibitors and cardiac remodeling. J Cardiovasc Transl Res. 2022;15(5):944\u201356.","journal-title":"J Cardiovasc Transl Res"},{"issue":"3","key":"1196_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RCI, Fiolet JWT, Stienen GJM, Coronel R, Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic na + through inhibition of the cardiac Na+\/H + exchanger in rats and rabbits. Diabetologia. 2017;60(3):568\u201373.","journal-title":"Diabetologia"},{"key":"1196_CR25","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","volume":"9","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW, et al. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying Heart Failure in diabetic patients. Front Physiol. 2018;9:1575.","journal-title":"Front Physiol"},{"issue":"1\u20132","key":"1196_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11010-014-2262-5","volume":"400","author":"NN Hamouda","year":"2015","unstructured":"Hamouda NN, Sydorenko V, Qureshi MA, Alkaabi JM, Oz M, Howarth FC. Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem. 2015;400(1\u20132):57\u201368.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"1196_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11373-005-7652-y","volume":"12","author":"MM Sugizaki","year":"2005","unstructured":"Sugizaki MM, Carvalho RF, Aragon FF, Padovani CR, Okoshi K, Okoshi MP, et al. Myocardial dysfunction induced by food restriction is related to morphological damage in normotensive middle-aged rats. J Biomed Sci. 2005;12(4):641\u20139.","journal-title":"J Biomed Sci"},{"key":"1196_CR28","doi-asserted-by":"publisher","first-page":"947294","DOI":"10.3389\/fendo.2022.947294","volume":"13","author":"MA Mengstie","year":"2022","unstructured":"Mengstie MA, Abebe EC, Teklemariam AB, Mulu AT, Teshome AA, Zewde EA, et al. Molecular and cellular mechanisms in diabetic Heart Failure: potential therapeutic targets. Front Endocrinol. 2022;13:947294.","journal-title":"Front Endocrinol"},{"issue":"10","key":"1196_CR29","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317.","journal-title":"Diabetologia"},{"issue":"15","key":"1196_CR30","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic Heart Failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1196_CR31","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ejhf.1473","volume":"21","author":"SR Yurista","year":"2019","unstructured":"Yurista SR, Sillj\u00e9 HHW, Oberdorf-Maass SU, Schouten E, Pavez Giani MG, Hillebrands J, et al. Sodium\u2013glucose co\u2010transporter 2 inhibition with empagliflozin improves cardiac function in non\u2010diabetic rats with left ventricular dysfunction after Myocardial Infarction. Eur J Heart Fail. 2019;21(7):862\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"1196_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijcard.2011.06.068","volume":"151","author":"MF Minicucci","year":"2011","unstructured":"Minicucci MF, Azevedo PS, Martinez PF, Lima ARR, Bonomo C, Guizoni DM, et al. Critical infarct size to induce ventricular remodeling, cardiac dysfunction and Heart Failure in rats. Int J Cardiol. 2011;151(2):242\u20133.","journal-title":"Int J Cardiol"},{"issue":"4","key":"1196_CR33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1536\/jhj.45.647","volume":"45","author":"K Okoshi","year":"2004","unstructured":"Okoshi K, Ribeiro HB, Okoshi MP, Matsubara BB, Gon\u00e7alves G, Barros R, et al. Improved systolic ventricular function with normal myocardial mechanics in compensated cardiac hypertrophy. Jpn Heart J. 2004;45(4):647\u201356.","journal-title":"Jpn Heart J"},{"issue":"5","key":"1196_CR34","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1159\/000354526","volume":"32","author":"MDM Cezar","year":"2013","unstructured":"Cezar MDM, Damatto RL, Martinez PF, Lima ARR, Campos DHS, Rosa CM, et al. Aldosterone blockade reduces mortality without changing cardiac remodeling in spontaneously hypertensive rats. Cell Physiol Biochem. 2013;32(5):1275\u201387.","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"1196_CR35","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/jcmm.14025","volume":"23","author":"DRA Reyes","year":"2019","unstructured":"Reyes DRA, Gomes MJ, Rosa CM, Pagan LU, Zanati SG, Damatto RL, et al. Exercise during transition from compensated left ventricular hypertrophy to Heart Failure in aortic stenosis rats. J Cell Mol Med. 2019;23(2):1235\u201345.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"1196_CR36","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1159\/000486115","volume":"44","author":"DRA Reyes","year":"2017","unstructured":"Reyes DRA, Gomes MJ, Rosa CM, Pagan LU, Damatto FC, Damatto RL, et al. N-acetylcysteine influence on oxidative stress and cardiac remodeling in rats during transition from compensated left ventricular hypertrophy to Heart Failure. Cell Physiol Biochem. 2017;44(6):2310\u201321.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"1196_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12872-019-1113-4","volume":"19","author":"K Okoshi","year":"2019","unstructured":"Okoshi K, Cezar MDM, Polin MAM, Paladino JR, Martinez PF, Oliveira SA, et al. Influence of intermittent fasting on myocardial infarction-induced cardiac remodeling. BMC Cardiovasc Disord. 2019;19(1):126.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"1196_CR38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0002-9629(15)40834-1","volume":"320","author":"AC Cicogna","year":"2000","unstructured":"Cicogna AC, Padovani CR, Okoshi K, Aragon FF, Okoshi MP. Myocardial function during chronic food restriction in isolated hypertrophied cardiac muscle. Am J Med Sci. 2000;320(4):244\u20138.","journal-title":"Am J Med Sci"},{"issue":"12","key":"1196_CR39","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1139\/y97-163","volume":"75","author":"LS Matsubara","year":"1997","unstructured":"Matsubara LS, Matsubara BB, Okoshi MP, Franco M, Cicogna AC. Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats. Can J Physiol Pharmacol. 1997;75(12):1328\u201334.","journal-title":"Can J Physiol Pharmacol"},{"key":"1196_CR40","doi-asserted-by":"publisher","first-page":"675778","DOI":"10.3389\/fphys.2021.675778","volume":"12","author":"LU Pagan","year":"2021","unstructured":"Pagan LU, Gomes MJ, Damatto RL, Lima ARR, Cezar MDM, Damatto FC, et al. Aerobic exercise during advance stage of uncontrolled arterial Hypertension. Front Physiol. 2021;12:675778.","journal-title":"Front Physiol"},{"issue":"1","key":"1196_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-017-0657-9","volume":"17","author":"R Gimenes","year":"2018","unstructured":"Gimenes R, Gimenes C, Rosa CM, Xavier NP, Campos DHS, Fernandes AAH, et al. Influence of apocynin on cardiac remodeling in rats with streptozotocin-induced Diabetes Mellitus. Cardiovasc Diabetol. 2018;17(1):15.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1196_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-2613.2006.00497.x","volume":"87","author":"RF Carvalho","year":"2006","unstructured":"Carvalho RF, Dariolli R, Justulin Junior LA, Sugizaki MM, Politi Okoshi M, Cicogna AC, et al. Heart Failure alters matrix metalloproteinase gene expression and activity in rat skeletal muscle. Int J Exp Pathol. 2006;87(6):437\u201343.","journal-title":"Int J Exp Pathol"},{"issue":"1","key":"1196_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000369683","volume":"35","author":"PF Martinez","year":"2015","unstructured":"Martinez PF, Bonomo C, Guizoni DM, Oliveira Junior SA, Damatto RL, Cezar MDM, et al. Influence of N- acetylcysteine on oxidative stress in slow-twitch soleus muscle of Heart Failure rats. Cell Physiol Biochem. 2015;35(1):148\u201359.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"1196_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1042\/bj1260049","volume":"126","author":"B Crabtree","year":"1972","unstructured":"Crabtree B, Newsholme EA. The activities of phosphorylase, hexokinase, phosphofructokinase, lactate dehydrogenase and the glycerol 3-phosphate dehydrogenase in muscles from vertebrates and invertebrates. Biochem J. 1972;126(1):49\u201358.","journal-title":"Biochem J"},{"issue":"1\u20132","key":"1196_CR45","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/0014-5793(75)81012-X","volume":"55","author":"H Hengartner","year":"1975","unstructured":"Hengartner H, Harris JI. Purification by affinity chromatography, properties and crystallisation of phosphofructokinase from thermophilic micro-organisms. FEBS Lett. 1975;55(1\u20132):282\u20135.","journal-title":"FEBS Lett"},{"issue":"20","key":"1196_CR46","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.1016\/S0021-9258(19)43342-5","volume":"248","author":"JM Cardenas","year":"1973","unstructured":"Cardenas JM, Dyson RD, Strandholm JJ. Bovine pyruvate kinases. I. Purification and characterization of the skeletal muscle isozyme. J Biol Chem. 1973;248(20):6931\u20137.","journal-title":"J Biol Chem"},{"issue":"3","key":"1196_CR47","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1042\/bj1540689","volume":"154","author":"PR Alp","year":"1976","unstructured":"Alp PR, Newsholme EA, Zammit VA. Activities of citrate synthase and NAD+-linked and NADP+-linked isocitrate dehydrogenase in muscle from vertebrates and invertebrates. Biochem J. 1976;154(3):689\u2013700.","journal-title":"Biochem J"},{"key":"1196_CR48","doi-asserted-by":"publisher","first-page":"108462","DOI":"10.1016\/j.diabres.2020.108462","volume":"170","author":"P Gillard","year":"2020","unstructured":"Gillard P, Schnell O, Groop PH. The nephrological perspective on SGLT-2 inhibitors in type 1 Diabetes. Diabetes Res Clin Pract. 2020;170:108462.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1196_CR49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12933-016-0442-1","volume":"15","author":"CM Rosa","year":"2016","unstructured":"Rosa CM, Gimenes R, Campos DHS, Guirado GN, Gimenes C, Fernandes AAH, et al. Apocynin influence on oxidative stress and cardiac remodeling of spontaneously hypertensive rats with Diabetes Mellitus. Cardiovasc Diabetol. 2016;15(1):126.","journal-title":"Cardiovasc Diabetol"},{"key":"1196_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/457848","volume":"2015","author":"C Gimenes","year":"2015","unstructured":"Gimenes C, Gimenes R, Rosa CM, Xavier NP, Campos DHS, Fernandes AAH, et al. Low intensity physical exercise attenuates cardiac remodeling and myocardial oxidative stress and dysfunction in diabetic rats. J Diabetes Res. 2015;2015:1\u201310.","journal-title":"J Diabetes Res"},{"issue":"1","key":"1196_CR51","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/jcsm.12814","volume":"13","author":"R Bamba","year":"2022","unstructured":"Bamba R, Okamura T, Hashimoto Y, Majima S, Senmaru T, Ushigome E, et al. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db\/db mice. J Cachexia Sarcopenia Muscle. 2022;13(1):574\u201388.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"1196_CR52","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/cvr\/cvad009","volume":"119","author":"R Madonna","year":"2023","unstructured":"Madonna R, Moscato S, Cufaro MC, Pieragostino D, Mattii L, Del Boccio P, et al. Empagliflozin inhibits excessive autophagy through the AMPK\/GSK3\u03b2 signalling pathway in diabetic cardiomyopathy. Cardiovasc Res. 2023;119(5):1175\u201389.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"1196_CR53","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/dom.14620","volume":"24","author":"J Seufert","year":"2022","unstructured":"Seufert J, Lanzinger S, Danne T, Bramlage P, Schmid SM, Kopp F, et al. Real-world data of 12\u2010month adjunct sodium\u2010glucose co\u2010transporter\u20102 inhibitor treatment in type 1 Diabetes from the German\/Austrian DPV registry: improved HbA1c without diabetic ketoacidosis. Diabetes Obes Metab. 2022;24(4):742\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1196_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Lin X, Chu Y, Chen X, Du H, Zhang H, et al. Dapagliflozin: a sodium\u2013glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGF\u03b21\/Smad signaling. Cardiovasc Diabetol. 2021;20(1):121.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1196_CR55","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/1061186X.2022.2064479","volume":"30","author":"CC Wang","year":"2022","unstructured":"Wang CC, Li Y, Qian XQ, Zhao H, Wang D, Zuo GX, et al. Empagliflozin alleviates myocardial I\/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK\/ATF4\/Beclin1 pathway. J Drug Target. 2022;30(8):858\u201372.","journal-title":"J Drug Target"},{"issue":"9","key":"1196_CR56","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1139\/y01-060","volume":"79","author":"MP Okoshi","year":"2001","unstructured":"Okoshi MP, Okoshi K, Pai VD, Pai-Silva MD, Matsubara LS, Cicogna AC. Mechanical, biochemical, and morphological changes in the heart from chronic food-restricted rats. Can J Physiol Pharmacol. 2001;79(9):754\u201360.","journal-title":"Can J Physiol Pharmacol"},{"issue":"1","key":"1196_CR57","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12933-015-0255-7","volume":"14","author":"JFC Guimaraes","year":"2015","unstructured":"Guimaraes JFC, Muzio BP, Rosa CM, Nascimento AF, Sugizaki MM, Fernandes AAH, et al. Rutin administration attenuates myocardial dysfunction in diabetic rats. Cardiovasc Diabetol. 2015;14(1):90.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1196_CR58","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/antiox11020336","volume":"11","author":"LU Pagan","year":"2022","unstructured":"Pagan LU, Gomes MJ, Gatto M, Mota GAF, Okoshi K, Okoshi MP. The role of oxidative stress in the aging heart. Antioxidants. 2022;11(2):336.","journal-title":"Antioxidants"},{"key":"1196_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pharmthera.2017.08.001","volume":"182","author":"H Noordali","year":"2018","unstructured":"Noordali H, Loudon BL, Frenneaux MP, Madhani M. Cardiac metabolism \u2014 a promising therapeutic target for Heart Failure. Pharmacol Ther. 2018;182:95\u2013114.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1196_CR60","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cjca.2017.12.029","volume":"34","author":"AC Carpentier","year":"2018","unstructured":"Carpentier AC. Abnormal myocardial dietary fatty acid metabolism and diabetic cardiomyopathy. Can J Cardiol. 2018;34(5):605\u201314.","journal-title":"Can J Cardiol"},{"issue":"4","key":"1196_CR61","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3390\/antiox12040896","volume":"12","author":"EA Rodrigues","year":"2023","unstructured":"Rodrigues EA, Lima ARR, Gomes MJ, Souza LM, Pontes THD, Pagan LU, et al. Influence of isolated resistance exercise on cardiac remodeling, myocardial oxidative stress, and metabolism in infarcted rats. Antioxidants. 2023;12(4):896.","journal-title":"Antioxidants"},{"issue":"22","key":"1196_CR62","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","volume":"147","author":"MJ Hundertmark","year":"2023","unstructured":"Hundertmark MJ, Adler A, Antoniades C, Coleman R, Griffin JL, Holman RR, et al. Assessment of cardiac energy metabolism, function, and physiology in patients with Heart Failure taking empagliflozin: the randomized, controlled EMPA-VISION Trial. Circulation. 2023;147(22):1654\u201369.","journal-title":"Circulation"},{"issue":"2","key":"1196_CR63","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cell.2016.05.071","volume":"166","author":"JZ Long","year":"2016","unstructured":"Long JZ, Svensson KJ, Bateman LA, Lin H, Kamenecka T, Lokurkar IA, et al. The secreted enzyme PM20D1 regulates lipidated amino acid uncouplers of mitochondria. Cell. 2016;166(2):424\u201335.","journal-title":"Cell"},{"key":"1196_CR64","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3389\/fphys.2019.00639","volume":"10","author":"AP Sowton","year":"2019","unstructured":"Sowton AP, Griffin JL, Murray AJ. Metabolic profiling of the diabetic heart: toward a richer picture. Front Physiol. 2019;10:639.","journal-title":"Front Physiol"},{"issue":"2","key":"1196_CR65","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1152\/ajpendo.1987.253.2.E202","volume":"253","author":"N Makino","year":"1987","unstructured":"Makino N, Dhalla KS, Elimban V, Dhalla NS. Sarcolemmal Ca2+ transport in streptozotocin-induced diabetic cardiomyopathy in rats. Am J Physiol-Endocrinol Metab. 1987;253(2):E202\u20137.","journal-title":"Am J Physiol-Endocrinol Metab"},{"issue":"2","key":"1196_CR66","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/ijms24021408","volume":"24","author":"MF Gholam","year":"2023","unstructured":"Gholam MF, Liu LP, Searcy LA, Denslow ND, Alli AA. Dapagliflozin treatment augments bioactive phosphatidylethanolamine concentrations in kidney cortex membrane fractions of hypertensive diabetic db\/db mice and alters the density of lipid rafts in mouse proximal tubule cells. Int J Mol Sci. 2023;24(2):1408.","journal-title":"Int J Mol Sci"},{"key":"1196_CR67","doi-asserted-by":"publisher","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","volume":"170","author":"A Arag\u00f3n-Herrera","year":"2019","unstructured":"Arag\u00f3n-Herrera A, Feij\u00f3o-Band\u00edn S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677.","journal-title":"Biochem Pharmacol"},{"key":"1196_CR68","doi-asserted-by":"publisher","first-page":"175521","DOI":"10.1016\/j.ejphar.2023.175521","volume":"942","author":"RS Farias","year":"2023","unstructured":"Farias RS, Silva-Aguiar RP, Teixeira DE, Gomes CP, Pinheiro AAS, Peruchetti DB, et al. Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic Kidney Disease. Eur J Pharmacol. 2023;942:175521.","journal-title":"Eur J Pharmacol"},{"key":"1196_CR69","doi-asserted-by":"publisher","first-page":"1109946","DOI":"10.3389\/fcvm.2023.1109946","volume":"10","author":"J Liu","year":"2023","unstructured":"Liu J, Wang Y, Zhang J, Li X, Tan L, Huang H, et al. Dynamic evolution of left ventricular strain and microvascular perfusion assessed by speckle tracking echocardiography and myocardial contrast echocardiography in diabetic rats: effect of dapagliflozin. Front Cardiovasc Med. 2023;10:1109946.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1196_CR70","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ehf2.14169","volume":"10","author":"C Dai","year":"2023","unstructured":"Dai C, Kong B, Shuai W, Xiao Z, Qin T, Fang J, et al. Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right Heart Disease. ESC Heart Fail. 2023;10(1):578\u201393.","journal-title":"ESC Heart Fail"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-023-01196-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T09:07:07Z","timestamp":1698743227000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-023-01196-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1186\/s13098-023-01196-6","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments and procedures were approved by the Animal Ethics Committee of Botucatu Medical School (n\u00ba 1320\/2019), Sao Paulo State University, UNESP, Botucatu, SP, Brazil.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}